These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20178720)

  • 1. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
    Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
    Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients.
    Theodoridis M; Passadakis P; Kriki P; Panagoutsos S; Yannatos E; Kantartzi K; Sivridis D; Vargemezis V
    Perit Dial Int; 2005; 25(6):564-9. PubMed ID: 16411523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW; Chang CH
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC; Matcham J; Gray SJ;
    Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
    Hahn D; Cody JD; Hodson EM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
    Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
    Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
    Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan.
    Kubota M; Hiramatsu M; Yamakawa M; Fukuhara S; Morita S; Iwasaki M; Akizawa T;
    Clin Exp Nephrol; 2011 Dec; 15(6):884-92. PubMed ID: 21898029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.